University of Monastir, Faculty of Science of Monastir, Laboratory of Heterocyclic, Chemistry, Natural Products and Reactivity, TeamMedicinal Chemistry and Natural, Products (LR11ES39), Department of Chemistry, Avenue of Environment, 5019 Monastir, Tunisia.
Pasteur Institute of Tunis, LR20IPT01, Laboratory of Biomolecules, Venoms and Theranostic Applications, 1002 Tunis, Tunisia; University of Tunis El Manar, 1068 Tunis, Tunisia.
Bioorg Chem. 2021 Sep;114:105071. doi: 10.1016/j.bioorg.2021.105071. Epub 2021 Jun 8.
Two series of 3,5-disubstituted isoxazoles (6a-e) and 1,4-disubstituted triazoles (8a-e) derivatives have been synthesized from tyrosol (1), a natural phenolic compound, detected in several natural sources such as olive oil, and well-known by its wide spectrum of biological activities. Copper-catalyzed microwave-assisted 1,3-dipolar cycloaddition reactions between tyrosol-alkyne derivative 2 and two series of aryl nitrile oxides (5a-e) and azides (7a-e) regiospecifically afforded 3,5-disubstituted isoxazoles (6a-e) and 1,4-triazole derivatives (8a-e), respectively in quantitative yields. Synthesized compounds were purified and characterized by spectroscopic means including 1D and 2D NMR techniques and HRMS analysis. The newly prepared hybrid molecules have been evaluated for their anticancer and hemolytic activities. Results showed that most derivatives displayed significant antiproliferative activity against human glioblastoma cancer cells (U87) in a dose-dependent manner. Compounds 6d (IC = 15.2 ± 1.0 μg/mL) and 8e (IC = 21.0 ± 0.9 μg/mL) exhibited more potent anticancer activity. Moreover, most derivatives displayed low hemolytic activity, even at higher concentrations which suggested that these classes of compounds are suitable candidates for further in vivo investigations. The obtained results allow us to consider the newly synthesized isoxazole- and triazole-linked tyrosol derivatives as promising scaffolds for the development of effective anticancer agents.
已从橄榄油等多种天然来源中检测到的天然酚类化合物酪氨酸(1)合成了两个系列的 3,5-二取代异恶唑(6a-e)和 1,4-二取代三唑(8a-e)衍生物,其具有广泛的生物活性。在铜催化微波辅助下,酪氨酸炔烃衍生物 2 与两个系列的芳基腈氧化物(5a-e)和叠氮化物(7a-e)之间发生 1,3-偶极环加成反应,以定量产率分别得到 3,5-二取代异恶唑(6a-e)和 1,4-三唑衍生物(8a-e)。合成的化合物通过光谱学方法(包括 1D 和 2D NMR 技术和 HRMS 分析)进行了纯化和表征。新制备的杂合分子已被评估其抗癌和溶血活性。结果表明,大多数衍生物以剂量依赖的方式对人神经胶质瘤癌细胞(U87)显示出显著的增殖抑制活性。化合物 6d(IC = 15.2 ± 1.0 μg/mL)和 8e(IC = 21.0 ± 0.9 μg/mL)表现出更强的抗癌活性。此外,大多数衍生物显示出低溶血活性,即使在较高浓度下也是如此,这表明这些类化合物是进一步体内研究的合适候选物。获得的结果使我们能够将新合成的异恶唑和三唑连接的酪氨酸衍生物视为开发有效抗癌剂的有前途的支架。